SLC5A2 and chronic kidney disease: In DAPA-CKD [9], SGLT2 inhibition results in a 19% reduction in CV mortality (HR 0.81, 95% CI 0.58 to 1.12) and similarly, in the heart failure population DAPA-HF [10] demonstrated a CV mortality benefit from SGLT2 inhibition of 18% (HR 0.82, 95% CI 0.69 to 0.98).